Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 307 participants.
Also called NCT01704261
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 307 participants
- Sponsor
- Registry
-
NCT01704261 -
2012-002612-10
-
- Main results
- A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01704261. Randomized; triple masking; primary purpose treatment. Start 2012-10-18 (actual); primary completion 2014-12-23 (actual). Results posted on 2015-11-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Omarigliptin
- Intervention (Drug)
- Matching placebo to Omarigliptin
- Intervention (Drug)
- Glimepiride
- Intervention (Drug)
- Metformin
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01704261- Content hash
4190608a62f44420df16badd282f186c3dffd3f97d106db7c881545ff572b5f3